Short answer · Medically reviewed summary · Last updated: 2026-04-07
TL;DR: Retinoblastoma is a rare eye cancer that primarily affects young children, first described in the early 19th century as "fungus hematodes." Over the last two centuries, our understanding has evolved from identifying it as a fatal malignancy to a highly treatable condition, driven by the discovery of the RB1 tumor suppressor gene and the shift toward eye-sparing therapies. When was Retinoblastoma first described in medical literature? The clinical history of retinoblastoma began in 1809 when Scottish surgeon James Wardrop provided the first detailed description of the tumor. At the time, he referred to it as "fungus hematodes" of the eye, noting its aggressive growth and tendency to protrude from the orbit.
What is the history of Retinoblastoma?
History of Retinoblastoma: when and how it was discovered, and the milestones in research since, medically reviewed.
TL;DR: Retinoblastoma is a rare eye cancer that primarily affects young children, first described in the early 19th century as "fungus hematodes." Over the last two centuries, our understanding has evolved from identifying it as a fatal malignancy to a highly treatable condition, driven by the discovery of the RB1 tumor suppressor gene and the shift toward eye-sparing therapies.
When was Retinoblastoma first described in medical literature?
The clinical history of retinoblastoma began in 1809 when Scottish surgeon James Wardrop provided the first detailed description of the tumor. At the time, he referred to it as "fungus hematodes" of the eye, noting its aggressive growth and tendency to protrude from the orbit. For much of the 19th century, the disease was poorly understood, often confused with other inflammatory or infectious conditions of the eye. It wasn't until 1864 that the German physician Hermann Hirschberg introduced the term "glioma retinae," reflecting the belief that the tumor originated from glial cells, a misconception that persisted for decades.
How did our understanding of Retinoblastoma evolve?
The true nature of retinoblastoma as a tumor of primitive retinal cells was finally clarified in the early 20th century, leading to its modern name. A major turning point occurred in 1971 when Dr. Alfred Knudson proposed the "two-hit hypothesis." This landmark theory explained why some cases of retinoblastoma are hereditary (occurring in both eyes) and others are sporadic (occurring in one eye). Knudson’s work was later confirmed by the identification of the RB1 gene in 1986, which was the first tumor suppressor gene ever discovered. This breakthrough fundamentally changed how clinicians approach the diagnosis and genetic counseling of families affected by retinoblastoma.
What are the major milestones in treating Retinoblastoma?
Historically, the treatment for retinoblastoma was radical, focusing solely on saving the child's life rather than the eye. Treatment evolution has progressed through several distinct stages:
- 1800s: Enucleation (surgical removal of the eye) was the only option, often performed too late to prevent metastasis.
- 1950s: The introduction of external beam radiation therapy allowed for the possibility of eye preservation.
- 1990s: Chemoreduction (using systemic chemotherapy to shrink the tumor) became the standard of care, significantly improving survival rates.
- 2000s-Present: Targeted delivery methods, such as intra-arterial and intravitreal chemotherapy, have revolutionized outcomes by delivering medication directly to the eye, minimizing systemic side effects.
How has patient advocacy changed the landscape?
In the past, the rarity of retinoblastoma—which affects approximately 1 in 15,000 to 20,000 live births—led to significant isolation for families. Today, global patient advocacy groups and platforms like DiseaseMaps.org provide a vital lifeline for the 8 members currently sharing their experiences. Advocacy has shifted the focus from mere survival to long-term quality of life, including survivors' psychosocial well-being, the management of late-term side effects from radiation, and the support of families navigating the complexities of genetic testing.
Next steps
- Consult with a pediatric ocular oncologist to review the latest eye-sparing treatment protocols.
- Speak with a clinical geneticist to understand the specific RB1 mutation status for your family.
- Join a dedicated patient support group to connect with others who have navigated the journey of retinoblastoma.
- Visit DiseaseMaps.org to share your story and connect with our growing community of rare disease patients and caregivers.
Medical disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a qualified healthcare professional regarding any medical condition.
References
- Orphanet: Retinoblastoma (ORPHA:790)
- NIH Genetic and Rare Diseases Information Center (GARD): Retinoblastoma
- OMIM (Online Mendelian Inheritance in Man): Retinoblastoma (RB1 gene; #180200)
- American Academy of Ophthalmology: History of Retinoblastoma Treatment
